Integrins as Therapeutic Targets for SARS-CoV-2

Front Cell Infect Microbiol. 2022 Apr 29:12:892323. doi: 10.3389/fcimb.2022.892323. eCollection 2022.

Timothy E Gressett^{1

2

3}, Danielle Nader⁴, Juan Pablo Robles⁵, Tione Buranda⁶, Steven W Kerrigan⁴, Gregory Bix^{1

2

3}

¹ Tulane University School of Medicine, Clinical Neuroscience Research Center (CNRC), New Orleans, LA, United States.
² Department of Neurology, Tulane University School of Medicine, New Orleans, LA, United States.
³ Tulane Brain Institute, Tulane University, New Orleans, LA, United States.
⁴ RCSI University of Medicine and Health Sciences, School of Pharmacy and Biomolecular Sciences (PBS), Dublin, Ireland.
⁵ Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Juriquilla, Mexico.
⁶ University of New Mexico Health Sciences Center (HSC), Department of Pathology, Albuquerque, NM, United States.

No abstract available

Keywords: ATN-161; RGD; SARS-CoV-2; cilengitide; integrins; therapeutic.

MeSH terms